ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Should we give "blueballs" a second chance? ; - )

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Aug 20, 2021 1:37pm

115 Views

Post# 33740457

RE:RE:Should we give "blueballs" a second chance? ; - )

BB, are you stupid to have 250K invested in PMN? Stating half your Investments are in PMN?

I call BS x 100000000

You could have bought Enbridge at 39
and would have been pocketing $21,000.00 in Dividends!

99% of the ppl on this Board are long term and have been holding the bag for YEARS! Do not listen to RC or any other "senior members"